**Tumor volume doubling times: Mean (Range, n)**

**Breast cancer**

14.51 days (-565.92 - 387.55, n = 957) [Yoo, et al. 2015]

185 days (66-521, n = 69) [Zhang, et al. 2017]

141 days (46-825, n = 66) [Ryu, et al. 2014]

ER+ = 241 +/- 166

HER2+ = 162 +/- 60

TN = 103 +/- 43

282 days (46-749, n = 31) [Fornvik et al., 2016]

94 days (25%-75% = 29-287 days, n = 395,188) [Weedon-Fekjær, et al. 2008]

**Ovarian Adenocarcinoma**

50-150 days [Robert and Maury, 2000] as cited in [Na, et al. 2011]

**Prostate Adenocarcinoma**

18.4 to 32.0 months (552 – 960 days, n = 4) [Werahera, et al. 2011]

10.2 months (306 days) (25%-75% = 2.75-36.2 months (83-1,086), n = 912) [Zharinov, et al. 2017]

7.9 months (237 days) (IQR 4.3-15.8 months, n = 277) [Jackson, et al. 2013]

**Hepatocellular Carcinoma**

85.7 days (11 – 851 days, n = 175) [An, et al. 2015]

2.37 months (71 days, n = 269) [Kim, et al., 2017]

112 – 204 days (30 – 600 days, review) [Trevisani, et al., 2008]

**Pancreatic Cancer**

144 days (64 – 255, n = 9) [Furikawa, et al., 2001]

(20 – 1,350 days, n = 188) [Mortenson, et al., 2017, Abstract]

**Colon Adenocarcinoma**

256 days (18 – 2,592 days, n = 44) [Choi, et al. 2013]

(92.4 to 1032.2 days, n = 6) [Tada, et al. 1984]

**Glioblastoma Multiforme**

29.8 days (−7832.4 - 8021.0 days, n = 106) [Stensjøen, et al. 2015]

(adjusted to 49.6 equivalent volume-doubling time)

17 days (1 – 87 days, n = 32) [Wang, et al. 2009]

References

An, C., Choi, Y. A., Choi, D., Paik, Y. H., Ahn, S. H., Kim, M. J., ... & Park, M. S. (2015). Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clinical and molecular hepatology, 21(3), 279.

Choi, S. J., Kim, H. S., Ahn, S. J., Jeong, Y. M., & Choi, H. Y. (2013). Evaluation of the growth pattern of carcinoma of colon and rectum by MDCT. Acta Radiologica, 54(5), 487-492.

Förnvik, D., Lång, K., Andersson, I., Dustler, M., Borgquist, S., & Timberg, P. (2016). Estimates of breast cancer growth rate from mammograms and its relation to tumour characteristics. Radiation protection dosimetry, 169(1-4), 151-157.

Furukawa, H., Iwata, R., & Moriyama, N. (2001). Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas, 22(4), 366-369.

Na, S., Hwang, J., Lee, H., Lee, J., & Lee, D. (2011). Rapidly growing ovarian endometrioid adenocarcinoma involving the vagina: A case report. Taiwanese Journal of Obstetrics and Gynecology, 50(4), 522-527.

Jackson, W. C., Johnson, S. B., Li, D., Foster, C., Foster, B., Song, Y., ... & Palapattu, G. S. (2013). A prostate-specific antigen doubling time of< 6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiation Oncology, 8(1), 170.

Kim, J. K., Kim, H. D., Jun, M. J., Yun, S. C., Shim, J. H., Lee, H. C., ... & Lee, Y. S. (2017). Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma. Digestive diseases and sciences, 62(10), 2923-2931.

Mortenson, T., Bigeh, A., Chen, Y., Malek-Ahmadi, M., Chen, K., Kundranda, M., & Chang, J. (2017). Heterogeneous growth rates of pancreatic adenocarcinoma by retrospective analysis of CT imaging data.

C.Y. Robert, M. Maurie, Chemotherapy, S.B. Jonathan, F.H. Neville (Eds.), Practical gynecologic oncology (3rd ed.), Lippincott Williams & Wilkins, Philadelphia (2000), p. 86

Ryu, E. B., Chang, J. M., Seo, M., Kim, S. A., Lim, J. H., & Moon, W. K. (2014). Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound. European radiology, 24(9), 2227-2235.

Stensjøen, A. L., Solheim, O., Kvistad, K. A., Håberg, A. K., Salvesen, Ø., & Berntsen, E. M. (2015). Growth dynamics of untreated glioblastomas in vivo. Neuro-oncology, 17(10), 1402-1411.

Tada, M., Misaki, F., & Kawai, K. (1984). Growth rates of colorectal carcinoma and adenoma by roentgenologic follow-up observations. Gastroenterologia Japonica, 19(6), 550-555.

Trevisani, F., Cantarini, M. C., Wands, J. R., & Bernardi, M. (2008). Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis, 29(7), 1299-1305.

Wang, C. H., Rockhill, J. K., Mrugala, M., Peacock, D. L., Lai, A., Jusenius, K., ... & Alvord, E. C. (2009). Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer research, 0008-5472.

Weedon-Fekjær, H., Lindqvist, B. H., Vatten, L. J., Aalen, O. O., & Tretli, S. (2008). Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Research, 10(3), R41.

Werahera, P. N., Glode, L. M., La Rosa, F. G., Lucia, M. S., Crawford, E. D., Easterday, K., ... & Hedlund, T. (2011). Proliferative tumor doubling times of prostatic carcinoma. Prostate cancer, 2011.

Yoo, T. K., Min, J. W., Kim, M. K., Lee, E., Kim, J., Lee, H. B., ... & Cho, N. (2015). In vivo tumor growth rate measured by US in preoperative period and long term disease outcome in breast cancer patients. PloS one, 10(12), e0144144.

Zharinov, G. M., Bogomolov, O. A., Neklasova, N. N., & Anisimov, V. N. (2017). Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients. Oncoscience, 4(1-2), 7.

Zhang, S., Ding, Y., Zhu, Q., Wang, C., Wu, P., & Dong, J. (2017). Correlation factors analysis of breast cancer tumor volume doubling time measured by 3D-ultrasound. Medical science monitor: international medical journal of experimental and clinical research, 23, 3147.